Business
Mustang Bio Announces Phase 1 Clinical Trial Evaluating MB-105 for Prostate Stem Cell Antigen-Positive Castration-Resistant Prostate Cancer Enrolling Patients at City of Hope
NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating
About this update from Mustang Bio, Inc.
[{"type":"text","content":"NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that City of Hope, a world-renowned independent cancer research and treatment center, has opened and is beginning to treat its first patients in a Phase 1 clinical trial of MB-105, a prostate stem cell antigen (PSCA) chimeric antigen receptor (CAR) T technology, for the treatment of prostate cancer. MB-105 was developed in the laboratory of Saul Priceman, Ph.D., assistant professor in City of Hope’s Department of Hematology & Hematopoietic Cell Transplantation and a scientist in the T Cell Therapeutics Research Laboratory led by Stephen Forman, M.D., leader of City of Hope’s Hematologic Malignancies and Stem Cell Transplantation Institute and the Francis & Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation.\n The clinical trial is one of the first CAR T trials for prostate cancer in the nation and can enroll up to 33 patients. Its primary endpoints are to define the side effects and best dose of PSCA CAR T cells in treating patients with PSCA-positive castration-resistant prostate cancer (CRPC) that has metastasized to other areas in the body. Secondary endpoints include assessing the expansion and persistence of PSCA CAR T cells, the clinical response based on Prostate Cancer Working Group 3 (PCWG3) criteria, survival outcomes and serum cytokine profiles in peripheral blood pre- and post-therapy, as well as describing the PSCA expression level on tumor cells prior to CAR T cell infusion and the relationship it may have with disease response and toxicities. The Prostate Cancer Foundation provided support for the preclinical research efforts that led to the trial’s development, as well as support for the clinical trial. Research is also supported by a generous gift from Barbara and Zach Horowitz and Gary Marsh and Jody Horowitz Marsh. “Patients with advanced prostate cancer are in urgent need of a therapy that could provide a more durable remission,” said Tanya Dorff, M.D., City of Hope associate clinical professor in the Department of Medical Oncology & Therapeutics Research, hea...